Cefiderocol (CFDC): A spy antibiotic future replacement of carbapenem Mahedi Md. Rezwan Ahmed1,12,*, Mounich Kamilia2, Hsu Chou-Yi3, Bhuiyan Jamilur Rahman4, Jasim Ihsan K.5, Khalaf Othman Mahjoob6, Darshan J C7, Wei Calvin R.8, Mushfique Mehrab Binte9, Syrmos Nikolaos10, Afrin Sadia1, Singh Peter11 1Department of Pharmacy, Comilla University, Bangladesh 2University Hassan 2, Sciences Faculty, Ain Chock, LIPE, Morocco 3Department of Pharmacy, Chia Nan University of Pharmacy and Science, Taiwan 4Department of Pharmacy, Jahangirnagar University, Bangladesh 5Department of Pharmacology, Al-Turath University College, Baghdad, Iraq 6College of Education, Al-Farahidi University, Baghdad, Iraq 7Assistant Professor, Department of Pharmacy Practice, Yenepoya Pharmacy College and Research Centre, Yenepoya (Deemed to be University), Ayush Campus, Naringana, Mangaluru, Karnataka, India, 575018 8Department of Research and Development, Shing Huei Group, Taipei, Taiwan 9Holy Family Red Crescent Medical College, Dhaka, Bangladesh 10Aristotle University of Thessaloniki, Thesaaloniki, Macedonia, Greece 11School of pharmacy, Brac University 12Research Secretary, Bangladesh Pharmacists’ Forum, Comilla University, Bangladesh *Corresponding Author E-mail: rezwanmahed747@gmail.com
Online Published on 5 February, 2024. Abstract Cefiderocol, also known as CFDC, is an antibiotic in the class of cephalosporins. It is from the third generation. It is effective against gram-negative bacteria. 2019 was the year that it was given US FDA approval for use in the treatment of UTIs. In recent years, there has been a dramatic rise in the prevalence of MDR due to the increased use of antibiotics. Carbapenem, which is a broad-spectrum antibiotic, is unable to treat the illness for this reason because bacteria have developed resistance to it. In this scenario, cefiderocol may be used for the therapy of this kind of infection, and it would also be of special assistance for the treatment of GNB in individuals who have few other therapeutic options available to them. For this review, studies published between 2007 and 2023 are the primary focus of the debate. This review's supporting materials were sourced via a combined search of PubMed, PubChem, and Google Scholar, including the terms "Cefiderocol," "Carbapenem," "Gram-negative Bacteria," "Carbapenem Resistance," and "Cefiderocol clinical trials" from 2007 until May 2023. The focus of this paper is the difference in mode of action of these two antibiotics and shows valid issues for carbapenem resistance. Top Keywords Cefiderocol, Carbapenem, UTIs, MDR, GNB, US-FDA, Etc. Top |